NEW YORK – Curesponse and Rafael Advanced Defense Systems said on Friday that they have partnered to develop a predictive oncology drug response assay.
Within the collaboration, Rehovot, Israel-based Curesponse will contribute its expertise in genomic and functional drug sensitivity testing, while Haifa, Israel-based Rafael will use its machine learning capabilities.
Together, the Israeli companies will implement machine learning into Curesponse's already developed cResponse platform, which uses 3D functional assays and preserves the tumor microenvironment ex vivo to predict a patient's likelihood of responding to cancer treatment. The platform also incorporates genomic sequencing to identify therapeutically targetable alterations.
"We are very pleased to work with Rafael, being supported by their world-leading AI capabilities and therein being able to implement the most sophisticated AI tools available today in our drug sensitivity platform," Curesponse CEO Guy Neev said in a statement. "The collaboration with Rafael will assist in further improving personalized oncology, which already helps cancer patients get the most efficacious drug for their disease."
In 2020, Curesponse announced expansion plans and established a laboratory in London.